HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

S Zeuzem Selected Research

Interferon-alpha (Interferon Alfa)

4/2013Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
1/2012[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
3/2010Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome.
6/2009The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection.
3/2009Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
11/2008Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy.
1/2007Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
9/2006[Difficult-to-treat patients with chronic hepatitis C].
5/2005[Treatment of hepatitis C virus infection].
5/2005The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


S Zeuzem Research Topics

Disease

53Chronic Hepatitis C
10/2016 - 01/2000
41Infections
01/2018 - 01/2000
21Hepatitis C
01/2017 - 01/2000
14Fibrosis (Cirrhosis)
11/2017 - 09/2000
12Liver Diseases (Liver Disease)
12/2016 - 01/2000
9Chronic Hepatitis B
01/2016 - 02/2000
9Neoplasms (Cancer)
05/2014 - 03/2000
8Hepatitis B
01/2017 - 02/2004
8Inflammation (Inflammations)
04/2015 - 12/2001
6Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
07/2013 - 02/2005
6Viremia
06/2009 - 03/2000
5Virus Diseases (Viral Diseases)
10/2016 - 08/2004
5Hepatocellular Carcinoma (Hepatoma)
04/2015 - 05/2005
4Liver Cirrhosis (Hepatic Cirrhosis)
04/2015 - 09/2000
4Fatigue
04/2015 - 10/2000
4Crohn Disease (Crohn's Disease)
09/2007 - 12/2001
3Insulin Resistance
12/2016 - 01/2000
3Body Weight (Weight, Body)
01/2014 - 03/2004
3Chronic Hepatitis (Chronic Active Hepatitis)
11/2013 - 07/2002
3Hepatitis
06/2010 - 08/2004
3Hemorrhage
11/2007 - 12/2004
2Lymphoma (Lymphomas)
01/2016 - 07/2012
2Acute Liver Failure (Fulminant Hepatic Failure)
10/2014 - 06/2009
2Coinfection
06/2012 - 10/2000
2Neoplasm Metastasis (Metastasis)
10/2009 - 08/2008
2Hyperthyroidism
03/2009 - 05/2000
2Massive Hepatic Necrosis
02/2009 - 05/2000
2Colorectal Neoplasms (Colorectal Cancer)
08/2008 - 06/2003
2Ulcerative Colitis
09/2007 - 02/2005
2Colitis
09/2007 - 03/2004
2Disease Progression
04/2007 - 10/2006
2Fatty Liver
01/2007 - 04/2000
2HIV Infections (HIV Infection)
12/2006 - 09/2006
2Necrosis
03/2004 - 08/2000
2Carcinoma (Carcinomatosis)
06/2003 - 12/2001
2Hepatic Encephalopathy
06/2002 - 05/2000
1Ascites
11/2017
1Type 2 Diabetes Mellitus (MODY)
12/2016
1Portal Hypertension
12/2016
1Pruritus (Itching)
04/2015
1Exanthema (Rash)
04/2015
1Dyslipidemias (Dyslipidemia)
08/2014

Drug/Important Bio-Agent (IBA)

31Antiviral Agents (Antivirals)IBA
01/2017 - 03/2000
29Ribavirin (Virazole)FDA LinkGeneric
10/2015 - 01/2000
23Interferon-alpha (Interferon Alfa)IBA
04/2013 - 01/2000
15InterferonsIBA
12/2016 - 10/2000
10RNA (Ribonucleic Acid)IBA
11/2012 - 10/2000
7Transaminases (Aminotransferases)IBA
06/2010 - 02/2000
6DNA (Deoxyribonucleic Acid)IBA
01/2018 - 02/2000
6Hepatitis B e AntigensIBA
01/2018 - 02/2001
5Hepatitis B Surface Antigens (HBsAg)FDA Link
01/2018 - 02/2009
5Pharmaceutical PreparationsIBA
10/2016 - 03/2003
5Interleukin-12 (IL 12)IBA
03/2004 - 02/2000
4Lamivudine (Epivir)FDA Link
10/2014 - 02/2001
4peginterferon alfa-2a (Pegasys)FDA Link
04/2013 - 12/2000
3Glucose (Dextrose)FDA LinkGeneric
12/2016 - 01/2000
3Insulin (Novolin)FDA Link
12/2016 - 01/2000
3albinterferon alfa-2bIBA
04/2013 - 03/2009
3Biological ProductsIBA
06/2011 - 12/2001
3CytokinesIBA
06/2010 - 07/2002
3EnzymesIBA
06/2009 - 06/2003
3Messenger RNA (mRNA)IBA
09/2007 - 03/2000
3Alanine Transaminase (SGPT)IBA
10/2006 - 01/2000
3Amantadine (Aman)FDA LinkGeneric
10/2003 - 10/2000
2SimeprevirIBA
04/2015 - 04/2015
2Proton Pump InhibitorsIBA
04/2015 - 03/2015
2Protease Inhibitors (Protease Inhibitor)IBA
04/2015 - 01/2012
2Indicators and Reagents (Reagents)IBA
04/2015 - 05/2014
2BilirubinIBA
10/2014 - 10/2003
2rheinIBA
07/2013 - 10/2009
2Immunosuppressive Agents (Immunosuppressants)IBA
06/2011 - 02/2005
2Aspartate Aminotransferases (Aspartate Transaminase)IBA
06/2010 - 01/2000
2Interleukin-18 (Interleukin 18)IBA
09/2007 - 12/2001
2Proteins (Proteins, Gene)FDA Link
03/2004 - 06/2003
2Interleukin-10 (Interleukin 10)IBA
03/2004 - 07/2002
1alisporivirIBA
10/2015
1SofosbuvirIBA
04/2015
1NucleotidesIBA
04/2015
1dasabuvirIBA
04/2015
1ledipasvirIBA
04/2015
1ombitasvirIBA
04/2015
1daclatasvirIBA
04/2015
1paritaprevirIBA
04/2015
1HLA-DP Antigens (HLA-DP)IBA
10/2014
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
08/2014
1Hypolipidemic Agents (Antihyperlipidemics)IBA
08/2014
1Fibric Acids (Fibrates)IBA
08/2014
125-hydroxyvitamin DIBA
05/2014
1hydroxide ionIBA
05/2014

Therapy/Procedure

63Therapeutics
12/2016 - 01/2000
4Liver Transplantation
07/2016 - 05/2001
3Drug Therapy (Chemotherapy)
07/2013 - 04/2007
3Retreatment
10/2003 - 01/2000
2Transplantation
07/2016 - 02/2005
2Stents
06/2013 - 11/2011
2Drug Tapering
03/2009 - 05/2005
2Duration of Therapy
02/2009 - 06/2006
2Neoadjuvant Therapy
08/2008 - 11/2007
1Surgical Portasystemic Shunt (Portosystemic Shunt)
11/2017
1Transjugular Intrahepatic Portasystemic Shunt
11/2017